Skip to main content
. 2017 Aug 21;8(42):73050–73062. doi: 10.18632/oncotarget.20377

Table 1. Descriptive characteristics of studies included in the meta-analysis.

Study Country Study design Time frame Cases (N) Age
(y)
Sex
(M/F)
Patients Interventions Study outcomes Follow-up duration Attrition (%)
Abramowicz 1970 International Multicenter RCT 1967–1969 38 NR NR Initial SRNS AZA vs P/NT CR and PR at 90 d, 3 mos. 18%
Choudhry 2009 India Single center RCT 2005–2007 41 3.5–6.0 25/16 Initial and late SRNS TAC vs CSA CR and PR at 12 mos., adverse effects 12 mos. 0%
D'Agati 2013 USA Multicenter RCT 2004–2009 138 NR 73/65 Initial SRNS CSA vs MMF CR and PR at 12 mos., adverse effects 12 mos. 1%
Elhence 1994 India Single center RCT 1990–1991 13 3–16 11/2 Initial and late SRNS OCPA vs ICPA CR at 6 mos., adverse effects 6 mos. 15%
Garin 1988 USA Single center RCT NR 8 3–18 6/2 SRNS CSA vs P/NT CR at 3 mos. 3 mos. 0%
Gulati 2012 India Multicenter RCT 2008–2010 131 2–16 86/45 Initial and late SRNS TAC vs ICPA CR and PR at 12 mos., adverse effects 12 mos. 5%
ISKDC 1974 International Multicenter RCT 1970–1972 31 NR NR Initial SRNS OCPA vs P/NT CR and PR at 12 mos., adverse effects 24 mos. 0%
Kleinknecht 1980 France Single center RCT NR 30 NR NR SRNS CHL vs P/NT CR at 6 mos. 6 mos. 0%
Lieberman 1996 USA Multicenter RCT NR 31 7–16 21/9 Initial SRNS CSA vs P/NT CR and PR at 6 mos., adverse effects 6 mos. 23%
Magnasco 2012 Italy Single center RCT 2007–2010 31 < 16 19/12 Initial and late SRNS RTCA vs P/NT CR at 12 mos., adverse effects 12 mos. 0%
Mantan 2008 India Single center RCT 2001–2003 52 1–18 35/17 Initial and late SRNS ICPA vs OCPA CR and PR at 6 mos., adverse effects 18 mos. 6%
Ohri 2010 India Single center RCT NR 35 1–12 17/18 Initial SRNS ICPA vs OCPA CR and PR at 6 mos., adverse effects 6 mos. 0%
Plank 2008 International Multicenter RCT 2001–2004 32 1–13 19/13 Initial SRNS CSA vs CPA CR and PR at 3 mos., adverse effects 12 mos. 33%
Ponticelli 1993 Italy Multicenter RCT NR 20 2–18 NR Initial SRNS CSA vs P/NT CR and PR at 12 mos., adverse effects 12 mos. 15%
Sinha 2015 India Multicenter RCT NR 60 1–18 NR SRNS TAC vs MMF Complete or PR at 12 mos. 12 mos. 0.0%
Tarshish 1996 International Multicenter RCT NR 60 1–16 NR Initial SRNS OCPA vs P/NT CR and PR at 6 mos., adverse effects 12 mos. 11%
Valverde 2010 Mexico Single center RCT NR 17 1–18 NR SRNS CSA vs TAC CR and PR at 12 mos., adverse effects 12 mos. 0%
Wu 2015 China Single center RCT 2008–2012 18 2–18 11/7 SRNS CPA vs MMF vs LEF CR at 6 mos. 12 mos. 18%

Notes: SRNS, steroid-resistant nephrotic syndrome; NR, not reported; RCT, randomized controlled trial; CSA, cyclosporin; ICPA, intravenous cyclophosphamide; TAC, tacrolimus, MMF, mycophenolate mofetil; OCPA, oral cyclophosphamide; LEF, leflunomide; CHL, chlorambucil; AZA, azathioprine; RTCA, rituximab-cyclosporin dual therapy; P/NT, placebo/nontreatment; CR, complete response; PR, partial response.

HHS Vulnerability Disclosure